Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Other Non-current Assets
Long-term assets not reported separately.
Zura Bio LimitedNASDAQ: ZURA
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 116.6% from a year ago
Other non-current assets stood at $1.51M at the end of Q1 FY2026, up 116.6% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -24.3% a year.
Context
- Other non-current assets amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +116.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.51M USD
- Year-over-year change
- +116.6%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.51M | +116.6% |
| FY2024 | 2024-12-31 | 698K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 3.49M | — |
| FY2021 | 2022-03-31 | 0 | — |
Other Non-current Assets vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 other non-current assets of $1.51M is the 5th highest of the 11 companies compared; the peer median is $744K.
- Its year-over-year change of +116.6% is the 3rd highest of 10, against a peer median of -21.4%.
- Other non-current assets amounts to 0.7% of total assets for ZURA, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $42.19B | +5202413.6% | +291.0% | 19.6% | |
| Mar 2026 | $4.74M | +157.2% | +606.6% | 4.8% | |
| Mar 2026 | $3.79M | -21.4% | -7.2% | 2.8% | |
| Mar 2026 | $2.03M | -89.0% | — | 0.8% | |
ZURAZura Bio Limited | Mar 2026 | $1.51M | +116.6% | -24.3% | 0.7% |
| Mar 2026 | $1.18M | -0.3% | +2.1% | 0.7% | |
| Mar 2026 | $312K | +0.0% | -29.5% | 0.1% | |
| Mar 2026 | $144K | -95.8% | -49.1% | 0.0% | |
| Mar 2026 | $3K | -99.8% | -21.1% | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ZURA) | $744K | -21.4% | -7.2% | 0.4% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.